Medicare spending analysis for Pulmonary Disease providers
Pulmonary Disease accounts for $12.0B in Medicare payments across 99.1K providers.
The specialty's average markup of 3.0x is below the overall Medicare average of 3.77x.
AI-generated analysis based on Medicare payment data.
Providers in this specialty flagged by the ML v2 fraud detection model
| Year | Payments | Services | Providers | YoY Change |
|---|---|---|---|---|
| 2014 | $1.3B | 20.1M | 9.2K | — |
| 2015 | $1.3B | 20.1M | 9.4K | +0.6% |
| 2016 | $1.3B | 19.7M | 9.6K | -2.5% |
| 2017 | $1.3B | 19.4M | 9.8K | -1.4% |
| 2018 | $1.3B | 18.9M | 10.0K | -1.9% |
| 2019 | $1.3B | 18.6M | 10.1K | -0.9% |
| 2020 | $1.1B | 15.4M | 10.1K | -11.9% |
| 2021 | $1.1B | 15.2M | 10.2K | +1.0% |
| 2022 | $1.0B | 14.3M | 10.3K | -9.6% |
| 2023 | $991.2M | 14.1M | 10.4K | -2.1% |
| # | Provider | State | Payments | Services | Avg/Service |
|---|---|---|---|---|---|
| 1 | Carmen Salvaterra | MD | $8.9M | 57.5K | $155.64 |
| 2 | Raja Devanathan | IN | $3.0M | 106.7K | $28.55 |
| 3 | Jonathan Wiesen | VA | $2.4M | 89.1K | $26.64 |
| 4 | Jason Karp | NY | $2.1M | 82.1K | $25.61 |
| 5 | Bradley Chipps | CA | $1.6M | 62.0K | $26.24 |
| 6 | Sanober Kable | TX | $1.4M | 41.0K | $35.12 |
| 7 | Michael Newan | FL | $1.4M | 41.0K | $33.78 |
| 8 | Don Wynn | TX | $1.4M | 40.5K | $33.80 |
| 9 | Abraham Ishaaya | CA | $1.3M | 39.9K | $33.54 |
| 10 | An Pham | PA | $1.3M | 36.7K | $35.88 |
| 11 | Viney Soni | CA | $1.3M | 13.2K | $99.88 |
| 12 | Allen Silvey | NJ | $1.2M | 18.5K | $65.80 |
| 13 | Olusegun Oseni | TX | $1.1M | 16.5K | $67.16 |
| 14 | Gail Schattner | NY | $1.1M | 40.9K | $26.49 |
| 15 | Glenn Giessel | VA | $1.1M | 28.6K | $36.86 |
| 16 | Jamie Hey | VA | $1.0M | 29.1K | $34.86 |
| 17 | Aleksander Shalshin | NY | $1.0M | 12.0K | $83.13 |
| 18 | Ashesh Desai | TX | $999.8K | 17.4K | $57.55 |
| 19 | Evan Restelli | NC | $998.0K | 41.8K | $23.90 |
| 20 | George Shahinian | CA | $976.4K | 9.5K | $103.27 |
| 21 | Shahryar Yadegar | CA | $962.0K | 15.2K | $63.29 |
| 22 | Robert Dermarkarian | FL | $954.3K | 19.8K | $48.30 |
| 23 | Theodossis Zacharis | FL | $945.2K | 27.0K | $34.98 |
| 24 | Ritsu Kuno | VA | $933.4K | 27.5K | $33.93 |
| 25 | Shyamsunder Subramanian | CA | $932.8K | 46.1K | $20.25 |
| Code | Description | Payments | Services | Avg/Service |
|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | $182.7M | 2.0M | $91.84 |
| 99291 | Critical care, first 30-74 minutes | $174.4M | 1.0M | $169.88 |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | $128.3M | 1.4M | $94.90 |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | $78.4M | 1.2M | $63.47 |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | $46.5M | 358.4K | $129.81 |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | $44.9M | 327.4K | $137.05 |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | $44.3M | 701.7K | $63.09 |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | $36.7M | 310.0K | $118.30 |
| 94729 | Test to examine how well the lungs exchange gases | $20.2M | 748.3K | $26.94 |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | $16.5M | 103.3K | $160.13 |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | $16.1M | 76.8K | $210.01 |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | $14.5M | 140.3K | $103.44 |
| 95810 | Sleep study in sleep lab (6 years or older) | $13.9M | 67.4K | $205.97 |
| 94726 | Test to determine lung volumes using sensors | $12.4M | 479.3K | $25.89 |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | $11.2M | 545.1K | $20.54 |
| J2357 | Injection, omalizumab, 5 mg | $10.9M | 361.4K | $30.11 |
| J2182 | Injection, mepolizumab, 1 mg | $9.0M | 397.4K | $22.71 |
| J0517 | Injection, benralizumab, 1 mg | $7.3M | 57.0K | $128.03 |
| 94010 | Test to measure expiratory airflow and volume | $6.9M | 457.7K | $15.06 |
| J0225 | Injection, vutrisiran, 1 mg | $5.9M | 1.9K | $3.1K |
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.